Cardiff Oncology price target raised to $17 from $13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cardiff Oncology (CRDF) to $17 from $13 and keeps a Buy rating on the shares following the Q4 report. The firm views the totality of the data for onvansertib plus chemo as “highly promising.”